來寶網Logo

熱門詞:生物顯微鏡 水質分析儀 微波消解 熒光定量PCR 電化學工作站 生物安全柜

現在位置首頁>技術資料首頁>行業動態>公司動態>阿斯利康與和記黃埔醫藥強強聯手 打造全球創新癌癥治療方案

阿斯利康與和記黃埔醫藥強強聯手 打造全球創新癌癥治療方案

和記黃埔醫藥2011年12月22日 15:17 點擊:2077

和記黃埔醫藥 英國阿斯利康AstraZeneca



 

中國上海,20111221日: 阿斯利康和記黃埔醫藥(上海)有限公司(簡稱“和記黃埔醫藥”)今日宣布,雙方簽署了一項合作協議,共同致力于沃利替尼(Volitinib, HMPL-504)在全球范圍內的開發、審批和銷售。和記黃埔醫藥是一家領先的中國新藥研發企業,而沃利替尼是一種小分子新型靶向治療藥物,是c-Met受體酪氨酸激酶的高選擇性抑制劑,用于癌癥治療。沃利替尼是和記黃埔醫藥在中國發現和開發而成,并即將投入I期臨床試驗。 

協議規定,沃利替尼在中國的開發將繼續由和記黃埔醫藥負責,由此產生的費用則由和記黃埔醫藥和阿斯利康雙方共同分擔。而阿斯利康將負責沃利替尼在全球其它國家和地區的開發并承擔所有研發費用。協議簽署后,阿斯利康將向和記黃埔醫藥支付2000萬美元首付款項。此外,如果臨床開發獲得成功且初步銷售業績喜人,和記黃埔醫藥將可能獲得高達1.2億美元收益。該協議還包括了未來在銷售上可能取得的里程碑付款和在凈銷售收入基礎上最高可達兩位數百分比提成的專利費。這項合作進一步彰顯了阿斯利康和和記黃埔醫藥的承諾,即在目前尚無有效治療手段的重大疾病領域為中國患者提供安全有效的創新藥物。
 
阿斯利康腫瘤創新藥物部負責人 Susan Galbraith 表示:“阿斯利康正著力開發和營銷創新的癌癥靶向治療方案。沃利替尼則為我們提供了一個極具吸引力的全球機會。這一合作代表了阿斯利康與和記黃埔醫藥對于中國市場的共同承諾,同時也使得雙方的能力得以互補和加強。”
 
和黃中國醫藥科技有限公司首席執行官賀雋表示:“沃利替尼是由和記黃埔醫藥自主研發的全新靶向抗癌新藥,擁有全球知識產權。與阿斯利康的合作,不僅能加快該產品在中國的臨床研究,更重要的是有利于推動其全球開發進程,使廣大癌癥患者有可能早日受益。此次合作再一次展示了和黃醫藥先進的自主創新意識,雄厚的技術實力和高質量的研究成果,標志著中國創新藥物研發邁出了走向世界的重要一步。”
 
參考資料
 
關于和記黃埔醫藥(上海)有限公司
 
和記黃埔醫藥(上海)有限公司(Hutchison MediPharma Limited,HMP中國領先的創新藥物研發企業,主要研發治療癌癥和自身免疫性疾病的創新藥物。和記黃埔醫藥目前擁有約 200 位科學家和員工。和記黃埔醫藥將世界一流的研發經驗、技術平臺與中國的資源相結合,開發了一系列高質量的臨床前和進入臨床研究階段的具有自主知識產權的創新藥物。
和記黃埔醫藥由和黃中國醫藥科技有限公司控股。更多詳情請登陸:www.hmplglobal.com
 
關于和黃中國醫藥科技有限公司
和黃中國醫藥科技有限公司是一家主要針對中國市場的醫療保健集團控股公司,于20065月在倫敦證卷交易所的另類投資市場掛牌交易。該公司致力于研究、開發、生產和銷售藥品和健康類消費品。
和黃中國醫藥科技有限公司由和記黃埔有限公司持有多數股權。和記黃埔有限公司是一家在香港聯合交易所有限公司上市的國際化公司。欲知更多詳情請訪問:www.chi-med.com  
 
關于 c-Met 信號通道
c-Met(也稱為HGFR)信號通道尤其在哺乳類動物正常生長和發育過程中具有特殊作用。然而有研究已表明,這種通道在不同的癌癥范圍內表現異常。沃利替尼是有效的高選擇性c-Met抑制劑,在一系列臨床前疾病模型中已證明其可有效地抑制腫瘤生長,尤其是對于c-Met基因擴增或c-Met 蛋白過度表達等c-Met 信號傳導異常的腫瘤具有明顯的抑制作用。此外這些生物標志物可能在后期階段臨床試驗中用于篩選有效臨床試驗受試患者。
 
關于阿斯利康
阿斯利康是一家以創新為驅動的全球綜合型生物制藥企業,致力于在消化、心血管、中樞神經、呼吸、腫瘤、麻醉和抗感染等領域,研制、開發、生產和營銷卓有成效的處方藥品。阿斯利康的業務遍及全球 100 多個國家,為全球數以萬計的患者提供創新藥品。更多詳情請登陸:www.astrazeneca.com 
 
關于阿斯利康(中國)
阿斯利康是中國市場領先的生物制藥企業之一,在消化、心血管、中樞神經、呼吸、腫瘤、麻醉和抗感染等重大疾病領域提供創新的高質量藥品。阿斯利康 2010 年在華銷售額超過 10 億美元。阿斯利康中國區總部位于上海,業務遍及中國主要城市,包括香港地區?,F有約5,000 名員工,分布在生產、銷售、臨床研究和新產品開發等領域。
 
阿斯利康中國創新研發中心(ICC)是公司的研發基地,于 2007 年投入運營。目前,ICC 已成為設施完備的研發中心,致力于傳遞候選藥物、概念驗證和藥品,并專注于針對亞洲患者的疾病。2011  1 月,公司在上海成立了全球第五個臨床運營中心。

AstraZeneca and Chi-Med enter into global collaboration to co-develop and commercialise novel cancer therapy

Wednesday, 21 December 2011

London, Wednesday, 21 December 2011: AstraZeneca and Hutchison MediPharma Limited (“HMP”), an R&D company majority owned by Chi-Med, today announce that they have entered into a global licensing, co-development, and commercialisation agreement for Volitinib (HMPL-504), a novel targeted therapy and a highly selective inhibitor of the c-Met receptor tyrosine kinase for the treatment of cancer. Volitinib, which will imminently enter Phase I testing, has been discovered and developed in China by HMP.

Under the terms of the agreement, development costs for Volitinib in China will be shared between HMP and AstraZeneca, with HMP continuing to lead the development in China. AstraZeneca will lead and pay for the development of Volitinib for the rest of the world. An initial cash payment of US$20 million is payable by AstraZeneca to HMP upon the signing of the agreement. In addition, HMP will receive up to US$120 million contingent upon the successful achievement of clinical development and first sale milestones. The agreement also contains possible significant future commercial sale milestones and up to double-digit percentage royalties on net sales. This collaboration further underscores AstraZeneca’s goal to provide innovative medicines for unmet medical needs for patients in China.

Susan Galbraith, Head of Oncology Innovative Medicines, AstraZeneca said: “Volitinib represents a highly attractive global opportunity for AstraZeneca as we seek to develop and commercialise novel, targeted cancer therapies. This collaboration with HMP represents our commitment to China and brings together two groups with highly complementary capabilities.”

Christian Hogg, Chief Executive Officer of Chi-Med said: “We are very much looking forward to collaborating with AstraZeneca around Volitinib. Our collaboration will support the development and commercialisation of this novel oncology innovation, discovered in China, to the global market on an accelerated basis, something we could not have done alone.” 

Enquiries

Chi-Med                                        Telephone: +852 2121 8200
Christian Hogg, CEO

Citigate Dewe Rogerson          Telephone: +44 20 7638 9571
Anthony Carlisle                          Mobile: +44 7973 611 888
David Dible                                   Mobile: +44 7967 566 919

Lazard & Co., Limited                Telephone: +44 20 7187 2000
Paul Gismondi
Nick Fowler

AstraZeneca Media
Esra Erkal-Paler                          Telephone: +44 20 7604 8030
Katja Toon                                    Telephone: +44 20 7604 8268
Andrea Conners                          Telephone: +1 302 885 7652

About HMP

HMP is a novel drug R&D company focusing on discovering, developing and commercialising innovative therapeutics in oncology and autoimmune diseases. With a team of around 200 scientists and staff, its pipeline is comprised of novel oral compounds for cancer and inflammation in development in North America, Europe, Australia and Greater China.

HMP is majority owned by Chi-Med. For more information please visit: www.hmplglobal.com

About Chi-Med

Chi-Med is the holding company of a healthcare group based primarily in China and was listed on the Alternative Investment Market of the London Stock Exchange in May 2006. It is focused on researching, developing, manufacturing and selling pharmaceuticals and health oriented consumer products.

Chi-Med is majority owned by Hutchison Whampoa Limited, an international company listed on the Main Board of The Stock Exchange of Hong Kong Limited. For more information please visit:www.chi-med.com

About the c-Met Signal pathway

The c-Met (also known as HGFR) signalling pathway has specific roles particularly in normal mammalian growth and development, however this pathway has been shown to function abnormally in a range of different cancers. Volitinib is a potent and highly selective c Met inhibitor, which has been demonstrated to inhibit the growth of tumours in a series of pre-clinical disease models, especially for those tumours with aberrant c-Met signalling such as gene amplification or c-Met over-expression. In addition these biomarkers provide the potential to explore patient selection strategies in later stage clinical trials.

About AstraZeneca

AstraZeneca is a global, innovation-driven biopharmaceutical business with a primary focus on the discovery, development and commercialisation of prescription medicines for gastrointestinal, cardiovascular, neuroscience, respiratory and inflammation, oncology and infectious disease. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information please visit:www.astrazeneca.com

About AstraZeneca in China

AstraZeneca is one the leading biopharmaceutical companies in China providing innovative, high quality medicines for some of the most serious disease areas and therapies, including cardiovascular, gastrointestinal, respiratory, neurological, cancer, inflammation and anesthesia.

AstraZeneca’s turnover in China was over $1 billion in 2010. The company employs approximately 5,000 staff working in manufacturing, sales and marketing, clinical research and new product development at the company’s headquarters in Shanghai and across sites in mainland China and Hong Kong.

The company’s research and development facilities include the AstraZeneca Innovation Centre China (ICC), which started operations in 2007. Today, ICC is a full-fledged discovery centre focused on delivering candidate drugs and ultimately Proof of Concepts (POCs) and medicines, with a focus on diseases that are more prevalent in Asian patients. In January 2011, the company also opened a global Clinical Operational Hub in Shanghai – one of five such hubs globally.

(來源: 和記黃埔醫藥 )


全年征稿 / 資訊合作

聯系郵箱:[email protected]

版權與免責聲明

  • 凡本網注明“來源:來寶網”的所有作品,版權均屬于來寶網,轉載請必須注明來寶網, http://www.vhyrck.live,違反者本網將追究相關法律責任。
  • 本網轉載并注明自其它來源的作品,目的在于傳遞更多信息,并不代表本網贊同其觀點或證實其內容的真實性,不承擔此類作品侵權行為的直接責任及連帶責任。其他媒體、網站或個人從本網轉載時,必須保留本網注明的作品來源,并自負版權等法律責任。
  • 如涉及作品內容、版權等問題,請在作品發表之日起一周內與本網聯系,否則視為放棄相關權利。


35选7开奖查询